Hanshow Recognized as 2024 Sample Vendor in Gartner® Hype Cycle™ Reports for Retail Technologies and Wireless Technologies
14.8.2024 16:00:00 EEST | Business Wire | Press release
Hanshow, a global leader in developing and manufacturing electronic shelf labels (ESLs) and digital store solutions, proudly announces its recognition as a Sample Vendor in the Gartner Hype Cycle for Retail Technologies, 2024, under the Smart Shelf category, as well as in the Gartner Hype Cycle for Wireless Technology, 2024, under the Bluetooth ESL category. The Gartner Hype Cycle reports evaluate the maturity and adoption of various retail technologies, providing valuable insights for retail CIOs to make informed investment decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807460853/en/
Hanshow‘s Holistic Green Store Solutions (Graphic: Business Wire)
According to the 2024 Hype Cycle for Retail Technologies report, “Smart shelves can provide critical real-time visibility to in-store, on-shelf availability; increase operational efficiency; guide customers and associates to discover products; and contribute inputs to Internet of Things (IoT)-based real-time store monitoring capabilities. Data from smart shelves can equip retailers to replicate a richer in-store experience, generating revenue uplift and delivering significant efficiency gains of store operations.”
Hanshow’s smart shelf technology and ESLs are positioned as high benefit innovations that are set to mature and gain widespread adoption within the next five to ten years. Hanshow’s smart shelf solutions integrate an advanced SaaS IoT management platform with devices such as ESLs and digital marketing to provide real-time inventory management, dynamic pricing, and customer engagement.
Hanshow was also recognized as a sample vendor in the 2024 Hype Cycle for Wireless Technologies under the Bluetooth ESL category. Bluetooth ESLs are highlighted by the report as a significant innovation - emerging technology with a high benefit rating and is expected to reach mainstream adoption within two to five years.
These capabilities significantly improve the efficiency of in-store operations and enhance the overall shopping experience and operational efficiency. ESLs are recognized for their ability to facilitate real-time, data-driven pricing and product information updates, crucial for retailers aiming to synchronize their digital and physical channels. Inclusion as a Sample Vendor in these Gartner Hype Cycle reports underscores Hanshow’s position as a leading innovator in the industry.
“We are honored to be recognized by Gartner as a Sample Vendor in the 2024 Hype Cycle for Retail Technologies and 2024 Hype Cycle for Wireless Technologies,” said Shiguo Hou, CEO of Hanshow. “This recognition validates our efforts in pioneering digital store solutions that help retailers optimize their operations, enhance customer engagement, and achieve sustainable growth.”
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
Gartner Disclaimer:
Gartner, Hype Cycle for Retail Technologies, 2024, By Analysis Sandeep Unni, Max Panther Hammond, Published 29 July 2024
Gartner, Hype Cycle for Wireless Technologies, 2024, Analysis By Nick Jones, Published 5 August 2024
Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807460853/en/
Contacts
info@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom